Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group
University of Washington
City of Hope Medical Center
Baylor Research Institute
Hoosier Cancer Research Network
GBG Forschungs GmbH
University of Kansas Medical Center
Dana-Farber Cancer Institute
Eli Lilly and Company
Merck Sharp & Dohme LLC
Eli Lilly and Company
National Cancer Institute (NCI)
Beth Israel Deaconess Medical Center
Sun Yat-sen University
UNICANCER
Eli Lilly and Company
Hoosier Cancer Research Network
Cantargia AB
ImmunityBio, Inc.
The National Center of Oncology, Azerbaijan
RenJi Hospital
Fudan University
Fudan University
Emory University
National Cancer Institute, Slovakia
RenJi Hospital
Baylor Research Institute
Nektar Therapeutics
Peking University First Hospital
Pfizer
Bayer
Fudan University
Fudan University
Eli Lilly and Company
The Netherlands Cancer Institute
The Netherlands Cancer Institute
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Dana-Farber Cancer Institute
Ottawa Hospital Research Institute
Dana-Farber Cancer Institute
Massachusetts General Hospital
National Taiwan University Hospital
Fudan University
Louisiana State University Health Sciences Center Shreveport
Canadian Cancer Trials Group
Eli Lilly and Company
RenJi Hospital
Eli Lilly and Company
University of Washington